Uridine triacetate

Updated on Jan 01, 2025

Edit

Comment

Trade names Vistogard, Xuriden ATC code A16AX13 (WHO) Onset of action Tmax = 2–3 hours Trade name Vistogard, Xuriden		Routes ofadministration Oral granules Legal status US: ℞-only ChemSpider ID 18897

Metabolism Pyrimidine catabolic pathway

Uridine triacetate (INN), formerly known as vistonuridine, is an orally active tri-acetylated prodrug of uridine used:

in the treatment of hereditary orotic aciduria (brand name Xuriden ZOOR-ə-den);

to treat patients following an overdose of chemotherapy drugs 5-fluorouracil (5-FU) or capecitabine regardless of the presence of symptoms, or who exhibit early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions (e.g., gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration (brand name Vistogard).

Uridine triacetate was developed, manufactured and distributed by Wellstat Therapeutics and it is marketed in USA by BTG. Also, It was granted breakthrough therapy designation by FDA in 2015.

References

Uridine triacetate Wikipedia

(Text) CC BY-SA